Clq receptors (ClqR.) have been identifed on a variety of somatic and cultured ceils including peripheral blood platelets. Since platelets are likely to encounter both circulating Clq multimers and Clq associated with the extracellular matrix after complement activation by the classical pathway, the present study was designed to assess the effect of fluid phase and immobilized Clq on platelet function. Platelet adhesion to Clq-coated surfaces was accompanied by the induction of fibrinogen receptors. Scatchard analysis of fibrinogen binding to adherent platelets revealed the binding of '~10,000 molecules of fibrinogen per platelet with a Ka of 0.1 _+ 0.03 /zM (mean _+ SD, n = 4). Furthermore, fluid phase Clq multimers were noted to aggregate platelets at doses > 5/~g/ml. This aggregation was preceded by a rise in inositol-l,4,5-trisphosphate (IP3) (6.9 _+ 2.4 pmoles/109 platelets at 15 s, n = 4), and activation of GPIIb-IIIa complexes supporting fibrinogen binding. Platelet aggregation in response to Clq multimers was accompanied by the aspirin-inhibitable release of granule contents and P-selectin (CD62) expression. Platelet aggregation was inhibited by the collagenous domain of Clq (c-Clq) and a monoclonal antibody directed against Clq receptors, suggesting the direct involvement of the 67-kD platelet ClqR. Antibodies against the very late antigen 2 or CD36 collagen receptors were without effect. Platelet exposure to Clq multimers was also accompanied by the expression of procoagulant activity, as demonstrated by the dose-dependent shortening of the kaolin recalcification time of normal plasma from 108 _ 12 s in the presence of unstimulated platelets to 62 _+ 14 s in the presence of platelets that had been preincubated (5 min, 37~ with 100 #g/ml multimeric Clq (n = 3). These data suggest that platelet interactions with Clq multimers or immobilized Clq, resulting in the activation of GPIIb-IIIa fibrinogen binding sites and the expression of P-selectin as well as platelet procoagulant activity, are likely to contribute to thrombotic events associated with complement activation and inflammation.
C lq is a 460,000-mol wt glycoprotein present in plasma at ~,75 #g/ml (1) . Clq circulates as a calcium-dependent complex with Clr2 and Clsz, forming the first component of complement, C1 (2) . Upon activation of C1 by circulating immune complexes or certain bacteria and viruses, Clr2 and Cls2 are disassembled by Cl-inactivator (3), leaving complexbound Clq with its collagen-like tail exposed and potentially available for binding to Clq receptors (ClqR.) (4) . Whereas the extravascular localization of free Clq is limited under normal conditions, selective accumulation of this protein has been observed in inflamed and injured tissues, particularly after vascular injury or enhanced vascular permeability (5, 6). Moreover, the secretion of Clq by lymphokineactivated monocytes or macrophages has been documented (7, 8) .
The interaction of Clq with its receptors on somatic and cultured cells has been reported to elicit a variety of biological responses (4) . In platelets, the interaction with monomeric Clq was first reported to inhibit collagen-induced platelet aggregation (9, 10) . The structural similarities between the NH2 terminus of Clq and collagen (11) suggested that Clq and collagen binding sites were identical. Recent studies (12) , however, have demonstrated the existence of distinct platelet membrane receptors for Clq and collagen. Under certain conditions, however, these sites demonstrate crossreactivity with regard to ligand binding (12) .
Since virtually all biologically important C1 activating substances, including immune complexes, RNA tumor viruses, and lipid A-rich LPS bind multiple Clq molecules, Clq is likely to circulate in multimeric or aggregated form after ac-tivation of the classical complement pathway (13, 14) . Unlike Clq monomers, Clq muhimers have been suggested to support platelet aggregation (9) . Because Clq has also been reported as a transient component of the extraceUular matrix (15) , the present study was designed to evaluate the response of platelets both to Clq muhimers in the fluid phase, and to immobilized Clq on plastic surfaces.
Materials and Methods

Platelet Preparation
Blood was collected from human volunteers after obtaining informed consent. The blood was anticoagulated with 0.1 vol 3.2% sodium citrate in the presence or absence of I mM aspirin. Plateletrich plasma (PRP) was prepared by centrifugation of whole blood at 280 g (15 rain, 22~ Washed platelets (WP) t were obtained after acidifying the PRP to pH 6.5 with 1 M dtric acid, centrifuging the sample (1,000 g, 20 min, 22~ and resuspending the resulting platelet pellet in 0.01 M Hepes-buffered modified Tyrode's solution containing no added calcium, 2 mM MgClz, and 2 mg/ml BSA (HBMT) (Sigma Chemical Co., St. Louis, MO) (16) .
Purification of Protein Ligands
Clq was isolated from human serum as described by Reid (17) . Digestion of Clq with pepsin to obtain the coUagen-like domain (c-Clq) was performed as previously described (18) . Purified Clq (1 rag/m1) in 0.23 M sodium acetate buffer, pH 5.2, was dialyzed against 0.01 M PBS, pH 7.2, for 48 h at 4~ The resulting material appeared cloudy and was designated muhimeric/aggregated Clq (agg-Clq). To rule out effects of bacterial contamination of aggClq preparations during dialysis, similar studies were performed using microfihered (0.2/~m) Clq, autoclaved dialysis buffers, and glassware. Sterile agg-Clq supported similar dose-dependent phtelet activation as nonsterile preparations (data not shown). Aggregated IgG (agg-IgG) was prepared by heat treatment (60~ 20 min) of protein A-purified, human IgG. Agg-lgG was tested for its ability to activate complement by hemolytic assay (19) . Fibrinogen was purified from fresh frozen plasma (20) and iodinated with lzsI and an immobilized oxidant (N-chlorobenzenesulfonamide : iodobeads; Pierce Chemical Co., Rockford, IL) according to the instructions provided by the manufacturer.
Antibodies to the 67-kD ClqR designated II1/D1 were purified from ascites (21) . mAbs recognizing the very late antigen (VLA) 2 collagen receptor (6F1) (22) were obtained as a gift from Dr. B. Coller, State University of New York (SUNY) at Stony Brook. mAbs (IOP36) against CD36, platelet glycoprotein IV (GPIV), were purchased from AMAC, Inc. (Westbrook, ME).
Preparation of Protein-coated Surfaces
Microtiter wells were exposed to purified Clq (80/~g/ml) or BSA (80/zg/ml) for 16 h at 4~ Unreactive sites were blocked for 60 n'fin at 37~ with 0.1% BSA. Wells were rinsed with HBMT before exposure to platelets.
Platelet Function Studies
PlateletAggregation. (20) after platelet stimulation with agg-Clq in the presence of increasing amounts of l~I-fibrinogen. Nonspecific binding was assessed in the presence of 10 mM EDTA or excess unlabeled fibrinogen (20) .
Fibrinogen Binding to Adherent Platelets. WP (1.25 x 107) were added to Clq-coated microtiter wells. After 30-min adhesion (22~ nonadherent ptatelets were removed, the wells rinsed three times with PBS, and platelet adhesion quantified in duplicate wells using the bicinchoninic acid protein assay (23) . Additional wells were exposed to increasing concentrations of l~sI-fibrinogen. After 60 min at 22~ wells were rinsed three times, and residual radioactivity quantified using a gamma counter. Nonspecific fibrinogen binding was evaluated in the presence of excess unlabeled fibrinogen. The specificity of mI-fibrinogen binding was further evaluated in the presence of 100/~M arginine, glycine, aspartic acid (ILGDS; Peninsula Labs., Inc., Belmont, CA), or after platelet exposure to a mAb (20 #g/ml) recognizing the ellro/33 integrin, GPllb-IIIa (10E5, a gift from Dr. B. Coller) (24) .
Serotonin Release. Platelets were labeled with 14C-serotonin, 5-hydroxy(side chain-2-14C)tryptamine creatinine sulphate (Amersham Corp., Arlington Heights, IL), in whole blood (25) . 14C-serotonin release was measured at maximum platelet aggregation in the presence of 5/~M imipramine to prevent reuptake of released serotonin. Samples were fixed with an equal volume of 2% formalin, placed on ice, centrifuged for 3 min at 12,000 g, and the supernatant radioactivity evaluated in a beta counter.
P-Selectin Expression. The secretion of platelet c~ granules with concomitant expression of the platelet c~ granule membrane protein designated P-selectin (CD62) was assessed after stimulating platelets with saturating concentrations of agg-Clq (100 #g/ml) (26) at 37~ for 10 rain. Platelet suspensions were subsequently fixed with paraformaldehyde (27) , washed, and exposed to a PElabeled monoclonal antiCD62 antibody (Becton Dickinson Immunocytometry Systems, San Jose, CA) (30 rain, 22~ Platelets were washed three times in PBS and evaluated qualitatively for fluorescence at the Center for Imaging and Analysis (SUNY at Stony Brook) using a microscope/camera (Axiophot; Carl Zeiss, Inc., Thornwood, NY). Resting PGE1 (10 #M)-treated platelets, or platelets preincubated with 100 #g/ml monomeric Clq, served as negative controls. Platelets stimulated with 50 mU/ml thrombin (a gift from Dr. John Fenton II, New York State Department of Health, Albany, NY) served as positive controls. Thrombin was neutralized with excess hirudin before platelet fixation.
lnositol-l,4,5-Triphosphate (IP3) Production. WP (2 x 109/ml)
were incubated at 37~ in the presence of 0.1 mg/ml apyrase and stimulated with 100/~g/ml agg-Clq. The reaction was terminated by adding 0.2 ml 1 M TCA per I ml of platelet suspension. After a 15-min incubation on ice, samples were centrifuged (1 rain, 12,000 g, 4~ The supernatant (1 ml) was removed, and IP3 quantified using an IP3 3H-radioreceptor assay kit (New England Nuclear Research Products, Boston, MA) as described by the manufacturer.
Platelet Procoagulant Activity. Platelet factor 3 (PF3) availability was measured by incubating 0.1 ml pooled normal plasma (George King Biomedical Co., Overland Park, KS) with 0.1 ml kaolin (20 mg/ml) (Sigma Chemical Co.). After 5 min at 37~ 0.2 ml of platelets was added, followed by CaC12 (0.1 ml of a 0.035 M stock solution). Clot formation was monitored using a semi-automated impedance device (fibrometer; BBL, Division of Becton Dickinson & Co., Cockeysville, MD).
Results
Platelet adhesion to Clq-coated surfaces (59,000-68,000 platelets/mm z) resulted in specific and saturable fibrinogen binding. Maximal binding was achieved after 60 min at 22~ Half-maximal binding was noted within 10 rain. Binding was inhibited in the presence of 100 #M KGDS and preincubation of platdets with a mAb (10E5) recognizing the platdet membrane GPIIb-IIIa complex (Table 1) . Assuming a 1:1 relationship between bound fibrinogen and GPIlb-IIIa, Scatchard analysis (28) of fibrinogen binding isotherms revealed the exposure of 10,000 _+ 3,000 platelet membrane receptors, binding fibrinogen with a Ka of 0.1 _+ 0.03 #M (n = 3), consistent with GPIIb-IIIa-fibrinogen interactions previously characterized in the fluid phase (20) .
In the fluid phase, platelet exposure to Clq multimers resulted in dose-dependent platelet aggregation (Fig. 1) . Platdet aggregation in response to agg-Clq occurred without delay, and was accompanied by t2sI-fibrinogen binding and 14C-serotonin release (Table 2 ). Maximal fibrinogen binding was Platdet aggregation and serotonin release in response to 20 #g/m1 agg-Clq were measured 5 rain after stirring samples in an aggregometer at 37~ in the presence of 100 #g/m1 fibrinogen and 5 #M imipramine. Values are expressed as percent rdative to maximal aggregation or total platelet 14C-serotonin, respectively. obtained in the presence of 30-75/zg/ml agg-Clq (Fig. 2) . Fibrinogen binding to phtelets in suspension was always higher than fibrinogen binding to platelets adhering to Clq-coated surfaces. This may reflect the extent of platdet stimulation and/or the potentially decreased accessibility of fibrinogen receptors on adherent platdets which bind fibrinogen only to their nonadherent surface. Platelet aggregation, fibrinogen binding, and serotinin release were all inhibited but not abrogated after pretreatment of platdets with 1 mM aspirin, confirming the involvement of cyclo-oxygenase-dependent synthesis of thromboxane A2 (29) and release of platelet granule contents. The release of ot granules was inferred from qualitative analysis of cell surface P-selectin expression by direct immunofluorescence (Fig. 3) . Interestingly, the extent of P-selectin expression by 100 Ixg/ml agg-Clq (Fig. 3 E) appeared similar to that noted after platelet stimulation with a standard dose of thrombin (Fig. 3 F) .
To rule out platelet activation via occupancy of FcyRII receptors (30) by potential trace agg-IgG contamination, fibrinogen binding was compared in response to agg-Clq or similar concentrations of agg-IgG. As summarized in Fig.  2 , agg-IgG was without effect at 22~ in unstirred systems. Moreover, agg-Clq-induced fibrinogen binding was inhibited in the presence of the collagen-like NH2-terminal domain of Clq (c-Clq) or mAbs (II1/D1) directed against the 67-kD Clq receptor (Table 1) . mAbs directed against the FcyRII receptor, the VLA-2 collagen receptor, or CD36/GPIV, also reported to function in platelet-collagen interactions (31), were without effect ( Table 1) .
Platelet stimulation with agg-Clq was associated with rapid IP3 production (Fig. 4) . To optimize IP3 generation, platelets were stimulated with 100 #g/ml agg-Clq. The reaction was terminated at 2, 15, and 30 s. Maximal IP3 production was observed within 15 s of platelet stimulation (Fig. 4) . By 30 s, IP3 levels decreased almost to baseline.
Platelet stimulation with agg-Clq was also accompanied by the expression of surface membrane procoagulant activity. As summarized in Table 3 , shortening of the kaolin recaldfication time of pooled normal plasma was observed in the presence of platelets activated with increasing concentrations of agg-Clq. Clotting times in the presence of un- Fig'are 3 . Phase contrast views of unstimulated (.4) phtdets and platelets stimulated with 100/~g/ml agg-Clq (B), or 50 mU/ml human thrombin (63. Immundhorescence views demonstrating P-selectin expression on unstimulated phtdets (D), phtdets stimulated with 100/~g/ml agg-Clq (E), or 50 mU/ml thrombin (F) using a PEconjugated anti CD-62 mAb. Same views as 3 A-C. x200. stimulated platelets or thrombin-stimulated platelets served as negative and positive controls, respectively.
Discussion
Clq receptors are present on numerous somatic and cultured cells where they mediate a variety of cell-specific reactions (4). Platelets possess *4,000 Clq binding sites per cell and bind Clq with a Kd of 3.5 x 10 -7 M in a divalent cation independent manner (26) . The present study characterizes platelet responses to agg-Clq in solution and to immobilized Clq on plastic surfaces. The data demonstrate the direct involvement of the 67-kD phtelet ClqR in Clq-induced platelet stimulation. This stimulation involves several surface membrane-associated events including IP3 production, activation of GPIIb-IIIa fibrinogen receptors, cyclo-oxygenasemediated thromboxane A2 formation supporting the release of platelet granule contents, and the expression of P-selectin and procoagulant activity.
Previous studies (9, 10) have described the interaction of soluble Clq monomers with human platelets. The structural similarity between Clq and collagen suggested a potential role for platdet Clq receptors in modulating collagen-induced platelet functions. Interestingly, studies with highly purified Clq monomers and monodonal as well as polyclonal anfi-ClqR. antibodies demonstrated that whereas Clq and anti-ClqR antibodies inhibited collagen-induced platelet aggregation and secretion at low concentrations of collagen, they did not affect the adhesion of platelets to collagen fibrils or collagen-coated surfaces (32) . Moreover, the effect of anti ClqR Abs and an Ab directed against the platelet VLA-2 receptor dearly indicated that platelet adhesion to Type I collagen and Clq was mediated by distinct receptors (12) . This concept is further supported by observations made in the present study demonstrating specific inhibition of agg-Clq-induced platelet stim- Washed phtdets were stimulated with 0.10 U/m1 human thrombin or agg-IgG (20-100 ~g/ml). Thrombin was neutralized with excess hirudin before adding 0.2 ml of the platelet suspension to 0.2 ml normal plasma preincubated 5 min (370C) with 10 mg/ml kaolin. Clotting was initiated by adding 0.1 ml CaClz (0.035 M). Values represent mean _+ SD, n = 3.
ulation by anti ClqK antibodies, whereas anti-VLA-2 Abs and Abs against the CD36 collagen receptor were without effect. Since circulating platelets are more likely to encounter Clq multimers (14) or Clq immobilized to extraceUular matrix components (15) than Clq monomers, the ability of aggClq and Clq coated sttrfaces to activate phtdets provides strong support for the hypothesis that occupancy of the ClqR may contribute to thrombotic events associated with complement activation and inflammation. For example, platelet aggregation is the sine qua non for hemostatic or thrombotic platelet plug formation. Platelet aggregation requires occupancy of surface membrane agonist receptors capable of signal transduction. The present study suggests that the platelet ClqK may be such a receptor, as ClqR occupancy was associated with rapid IP3 formation. IP3 is an intracellular messenger that serves to raise cytosolic calcium (33) . Increases in intraplatelet calcium levels are associated with changes in phtelet membrane GPIIb-IIIa expression from an inactive to an active conformation. Indeed, platelet activation with agg-Clq or immobilized Clq in the present study was accompanied by specific and saturable fibrinogen binding. This bound fibrinogen is thought to be primarily responsible for platelet cohesion.
Platelet stimulation by agg-Clq was also accompanied by the release of platelet-dense granule serotonin, o~ granule secretion was inferred from cell surface P-selectin expression. Dense bodies contain not only serotinin, but also ADP which is an important agonist and may function to attract additional platelets to the site of a growing thrombus by expression of active GPIIb-IIIa complexes (34) . In addition, dense bodies contain biogenic amines that may participate in inflammatory reactions. In contrast, the release of ot granule contents includes a number of adhesive proteins such as fibrinogen, fibronectin, and thrombospondin, that may serve to reinforce phtelet-platelet interactions (35) . Secretion of ot granule contents is also accompanied by the surface expression of an c~ granule membrane protein, P-sdectin, previously referred to as GMP 140 or PADGEM (36, 37) . P-selectin has been shown to mediate the adhesion of nentrophils and monocytes to activated platelets in a calcium-dependent manner (37) .
Platelet ct granule secretions also contain the active form of coagulation factor V (Va) (38) . This, in combination with surface membrane changes leading to the exposure of negatively charged phospholipids (phosphatidylserine, phosphatidylinositol), encompasses PF3 procoagulant activity (39) . PF3 activity is essential for efficient thrombin generation leading to fibrin clot formation. Indeed, exposure ofplatelets to agg-Clq in the present study lead to dose-dependent PF3 generation, as measured by the kaolin recalcification time, a standard assay for the evaluation of platelet procoagnlant activity (40) .
Since platelet Clq receptors were previously found to participate in immune complex localization via immune complex association with the globular head region of Clq (41), the question arises as to whether ClqK occupancy by the coUagen-like NH2-terminal region of Clq is physiologically beneficial or detrimental. Based on available data, low concentrations of Clq multimers (<5-10 #g/ml), formed after binding immune complexes, certain bacteria or viruses, may participate in clearance mechanisms, and/or antigen presentation to lymphoid cells of the reticuloendothelial system. In contrast, high concentrations of agg-Clq appear likely to contribute to thrombotic and inflammatory reactions.
